<DOC>
	<DOCNO>NCT01294878</DOCNO>
	<brief_summary>By hypothesise Interstitial Cystitis allergic disorder urogenital system link mast-cells , current therapy omalizumab may represent potential non symptomatic strategy treatment IC/BPS</brief_summary>
	<brief_title>Omalizumab Interstitial Cystitis/Bladder Pain Syndrome</brief_title>
	<detailed_description>Interstitial cystitis/Bladder Pain Syndrome chronic inflammatory disease bladder , characterize pain pelvic region frequent need urinate . So far effective treatment uncommon distress condition . The objective preliminary study evaluate efficacy omalizumab treatment Interstitial Cystitis/Bladder Pain Syndrome , evaluate visual analogue score ( VAS ) pain urgency- frequency , O'Leary-Sant IC symptom problem index questionnaire ( primary outcome ) , PUF questionnaire Patient Global Assessment questionnaire , urination diary ( secondary outcome ) . Three female adult patient ( 24-34 year ) suffer form Interstitial Cystitis chronic bladder pain include study . The omalizumab dose calculate basis body weight basal level total serum IgE . Treatment administer subcutaneously every 2 4 week ( accord calculate total dose ) total 48 week . Each vial contain 150 mg active compound , therefore number injection administration vary 1 3 , depend total dose use . Patients allow take drug use IC ( Fibrase , Pelvilen , Normast , Quercetin , Chondroitin , Glucosamine per o ) . During screen process , dosage drug establish stably maintain 4 week run-in period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Female patient 18 year , range body weight 20 150 kg , provide write informed consent In patient diagnosed IC/PBS underwent treatment , basal level total serum IgE 30 700 IU/ml patient show positive allergic anamnesis ( asthma , rhinitis , atopic dermatitis , etc . ) Diagnosis IC/PBS perform accord criterion establish National Institute Health Consensus Conference patient symptoms least 3 month . Cytoscopy perform accord clinical indication Pregnancy , breastfeed . Fertile woman use secure contraceptive method ( hormonal double barrier method ) . Hysterectomized surgically sterilize woman ( tubal ligation ) menopause woman admit study . Clinically relevant medical condition ( neoplasia , infection , hematologic , renal , hepatic , cardiovascular , hormonal gastrointestinal pathology ) within 3 month prior study . Other specific criterion include patient positive anamnesis bladder cancer affect actinic cystitis , vaginitis , symptomatic bladder urethral diverticulum , active genital herpes , bladder urethral lithiasis . Urination frequency le 5 time per day . Known hypersensitivity omalizumab component , excipients include ( monoclonal antibody , polyclonal gamma globulin ) Alcohol drug abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>anti-IgE treatment</keyword>
	<keyword>interstitial cystitis/bladder pain syndrome</keyword>
	<keyword>omalizumab</keyword>
</DOC>